# A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

> **NCT07123090** · PHASE2 · RECRUITING · sponsor: **Stephanie Berg** · enrollment: 25 (estimated)

## Conditions studied

- Metastatic Renal Cell Carcinoma
- Metastatic Renal Cancer
- Renal Cell Carcinoma
- Advanced Clear Cell Renal Cell Carcinoma
- Kidney Cancer
- Translocation Renal Cell Carcinoma

## Interventions

- **DRUG:** Sasanlimab
- **DRUG:** Palbociclib
- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT07123090
- **Lead sponsor:** Stephanie Berg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-24
- **Primary completion:** 2026-10-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07123090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07123090, "A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07123090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*